Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label continuation study of oral AKT inhibitor afuresertib
2014-002041-22Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afuresertib in multiple myeloma (MM), hematopoietic malignancies, Nonhematologic neoplasms and 1 more, sponsored by Novartis. Primary endpoint: Duration of afuresertib treatment. Started Dec 2014; status: terminated.
02
Drugs
afuresertib
03
Conditions
multiple myeloma (MM)hematopoietic malignanciesNonhematologic neoplasmsNeoplasm
Beyond the preview
Go deeper on 2014-002041-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002041-22.